p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP
Cell Reports · 2023
DOI: 10.1016/j.celrep.2023.113426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Yingdan Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shan…. Hauptthemen laut MEDLINE: Neoplasms, Phosphofructokinase-1, Type C. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy. Here, we report that the human carboxymethylenebutenolidase homolog (carboxymethylenebutenolidase-like [CMBL]) acts as a tumor suppressor by reprogramming glycolysis in colorectal cancer (CRC). The anti-cancer action of CMBL is mediated through its interactions with the E3 ubiquitin ligase TRIM25 and the glycolytic enzyme phosphofructokinase-1 platelet type (PFKP). Ectopic CMBL enhances TRIM25 binding to PFKP, leading to the ubiquitination and proteasomal degradation of PFKP. Interestingly, CMBL is transcriptionally activated by p53 in response to genotoxic stress, and p53 activation represses glycolysis by promoting PFKP degradation. Remarkably, CMBL deficiency, which impairs p53's ability to inhibit glycolysis, makes tumors more sensitive to a combination therapy involving the glycolysis inhibitor 2-deoxyglucose. Taken together, our study demonstrates that CMBL suppresses CRC growth by inhibiting glycolysis and suggests a potential combination strategy for the treatment of CMBL-deficient CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Depart…
- Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
- State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University, Guangzhou 510060, China.
- Department of Lymphoma Medicine (Breast Cancer & Soft Tissue Tumor Medicine), Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.
Förderung
- Innovative Research Team of High-level Local University in Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Huang, Y., Xiong, C., Wang, C., Deng, J., Zuo, Z., Wu, H., Xiong, J., Wu, X., Lu, H., Hao, Q., & Zhou, X. (2023). p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113426
Vancouver
Huang Y, Xiong C, Wang C, Deng J, Zuo Z, Wu H, et al. p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP. Cell Reports. 2023. doi:10.1016/j.celrep.2023.113426
BibTeX
@article{Huang2023,
author = {Huang, Yingdan and Xiong, Chen and Wang, Chunmeng and Deng, Jun and Zuo, Zhixiang and Wu, Huijing and Xiong, Jianping and Wu, Xiaohua and Lu, Hua and Hao, Qian and Zhou, Xiang},
title = {p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP},
journal = {Cell Reports},
year = {2023},
doi = {10.1016/j.celrep.2023.113426}
}
EUVIMED